Ondansetron
NDC 71335-1731, Ondansetron, tablet, orally disintegrating, from Bryant Ranch Prepack.
- Product NDC
- 71335-1731
- Status
- Listed
- Labeler
- Bryant Ranch Prepack
- Dosage form
- TABLET, ORALLY DISINTEGRATING
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application
- ANDA090469
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/71335-1731 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- ONDANSETRON8 mg/1
Pharmacologic classes
Serotonin 3 Receptor Antagonists [MoA]; Serotonin-3 Receptor Antagonist [EPC]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 71335-1731-0 | 71335173100 | 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-0) |
| 71335-1731-1 | 71335173101 | 30 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-1) |
| 71335-1731-2 | 71335173102 | 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-2) |
| 71335-1731-3 | 71335173103 | 5 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-3) |
| 71335-1731-4 | 71335173104 | 4 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-4) |
| 71335-1731-5 | 71335173105 | 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-5) |
| 71335-1731-6 | 71335173106 | 14 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-6) |
| 71335-1731-7 | 71335173107 | 60 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-7) |
| 71335-1731-8 | 71335173108 | 12 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-8) |
| 71335-1731-9 | 71335173109 | 90 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (71335-1731-9) |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/2d1b8953-7ff5-4e91-ba97-3ba5c6ea8f71
Use it
Look up 71335-1731 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/71335-1731 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 71335-1731. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.